StreetInsider.com News Articles

AptarGroup names Virginie Maes as president of its pharma unit

Thu, 22 Oct 2026 17:30:18 -0400

AptarGroup, Inc. (NYSE: ATR) has appointed Virginie Maes as president of Aptar Pharma, effective January 1, 2027, according to a press release from the Crystal Lake, Illinois-based company.

Maes currently leads the global Flexibles Pharma and Medical packaging business at Amcor, overseeing operations across North America, Latin America, EMEA and Asia. Prior to her current role, she held senior leadership positions at Amcor spanning pharma, medical, strategy and business development.

Earlier in her career, Maes worked at McKinsey & Company, Terra Firma Capital Partners and Morgan Stanley. She holds an MBA from Harvard Business School, a Master's in Financial Management from Vlerick

Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business

Thu, 22 Oct 2026 17:30:00 -0400

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced the appointment of Virginie Maes as President of Aptar Pharma, effective January 1, 2027.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022738970/en/

Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business

Maes joins Aptar from Amcor, where she currently leads its

Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business

Thu, 22 Oct 2026 17:30:00 -0400

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022738970/en/

Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business

Maes joins Aptar from Amcor, where she currently leads its

Aptar Pharma wins CE marking for LuerVax intranasal vaccine device

Wed, 14 Oct 2026 17:01:00 -0400

AptarGroup, Inc. (NYSE: ATR) announced that its LuerVax intranasal delivery device and accompanying Spray Divider have received CE marking under the EU Medical Device Regulation, indicating the products meet European general safety and performance requirements for medical devices.

LuerVax is designed for administration of vaccines by healthcare professionals when connected to a compatible LuerLock syringe. The optional Spray Divider enables delivery of two sequential sprays, one per nostril, and is available in two sizes, 200 µL and 500 µL, for use with corresponding LuerLock syringes.

The devices are classified as Class I non-sterile, single-use medical devices under the MDR and are intended

Aptar Announces CE Marking for LuerVax® and Accompanying Spray Divider, Strengthening Support for Vaccine Developers

Wed, 14 Oct 2026 17:00:00 -0400

Milestone strengthens Aptar Pharma’s support for intranasal vaccine development from clinical studies through commercialization

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- Aptar Pharma, part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its LuerVax® intranasal delivery device and accompanying Spray Divider have been CE marked under the EU Medical Device Regulation (MDR), indicating that they meet the European general safety and performance requirements for medical devices. This milestone expands Aptar Pharma’s support for customers developing innovative intranasal vaccine products.

This press release features multimedia. View the

Aptar Announces CE Marking for LuerVax® and Accompanying Spray Divider, Strengthening Support for Vaccine Developers

Wed, 14 Oct 2026 17:00:00 -0400

Milestone strengthens Aptar Pharma’s support for intranasal vaccine development from clinical studies through commercialization

This press release features multimedia. View the

UBS Starts AptarGroup (ATR) at Neutral

Thu, 08 Oct 2026 16:10:51 -0400

UBS initiates coverage on AptarGroup (NYSE: ATR) with a Neutral rating and a price target of $135.00.

For an analyst ratings summary and ratings history on AptarGroup click here. For more ratings news on AptarGroup click here.

Shares of AptarGroup closed at $120.43 yesterday.

Wells Fargo Assumes AptarGroup (ATR) at Overweight

Thu, 08 Oct 2026 04:58:47 -0400

Wells Fargo analyst Richard C Carlson assumes coverage on AptarGroup (NYSE: ATR) with a Overweight rating and a price target of $155.00.

For an analyst ratings summary and ratings history on AptarGroup click here. For more ratings news on AptarGroup click here.

Shares of AptarGroup closed at $120.43 yesterday.

Deutsche Bank Starts AptarGroup (ATR) at Buy

Wed, 07 Oct 2026 07:26:48 -0400

Deutsche Bank analyst Justin Bowers initiates coverage on AptarGroup (NYSE: ATR) with a Buy rating and a price target of $150.00.

For an analyst ratings summary and ratings history on AptarGroup click here. For more ratings news on AptarGroup click here.

Shares of AptarGroup closed at $120.25 yesterday.

Form 8-K APTARGROUP, INC. For: Sep 21

Mon, 21 Sep 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260921/27085997.html

Aptar and Mass General Hospital team up on nose-to-brain drug delivery

Mon, 14 Sep 2026 17:01:03 -0400

AptarGroup, Inc. (NYSE: ATR) has signed a research collaboration agreement with Massachusetts General Hospital (MGH) to develop a predictive platform for nose-to-brain (N2B) drug delivery, according to a press release from the company.

The collaboration is led by Alice Stanton, PhD, Assistant Professor and Investigator in the Center for Genomic Medicine at Massachusetts General Brigham and Assistant Professor of Neurology at Harvard Medical School. The research will combine in vitro, in vivo and computational technologies to characterize the mechanisms, pathways and kinetics of nose-to-brain transport across a range of molecular classes and physicochemical properties.

The project aims to develop a New Approach

Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

Mon, 14 Sep 2026 17:00:00 -0400

Goal is to help pharmaceutical innovators evaluate opportunities earlier and accelerate future central nervous system pipelines

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it has signed an agreement for a research collaboration led by Alice Stanton, PhD from Massachusetts General Hospital (MGH) to advance the science of nose-to-brain (N2B) drug delivery.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914424839/en/

Aptar and Massachusetts General Hospital Collaborate
</article>
<article>
<h1>Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery</h1>
<p>Mon, 14 Sep 2026 17:00:00 -0400</p>
<p class=

Goal is to help pharmaceutical innovators evaluate opportunities earlier and accelerate future central nervous system pipelines

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it has signed an agreement for a research collaboration led by Alice Stanton, PhD from Massachusetts General Hospital (MGH) to advance the science of nose-to-brain (N2B) drug delivery.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914424839/en/